Published Medical Literature

Clinical Implications of a Complex Karyotype in AML in Children

Variant Acute Promyelocytic Leukemia: Genetic Knowledge May Help to Guide Treatment

Real-World Practice: Venetoclax Combinations in Patients With AML in Israel

Allogeneic Hematopoietic Stem Cell Transplantation for Therapy-Related AML

Acute Myeloid Leukemia and Spontaneous Splenic Rupture: Case Report

Mesothelin Under Study as Diagnostic and Therapeutic Target in AML

Consolidation Treatment in AML: Comparing Intermediate and High Dosing of Cytarabine

MLL Gene Rearrangements in Pediatric AML: Case Report

Potential Drug Candidates Identified for Pediatric Subtype of AML

Can Next-Generation Sequencing Help to Improve Outcomes in Elderly Patients With AML?

Is Lenalidomide Effective in Pediatric Patients With Resistant AML?

Older Patients With Untreated AML: Azacitidine Versus Triplet Regimen

Pilot Study of Vincristine Sulfate Liposome Injection in Resistant AML

Impact of Induction Chemotherapy on RAS Mutations in AML

In Vitro Responsiveness to Chemotherapy May Predict Responses to Treatment in AML

MRD Assessment: Refining Complete Remission in Elderly Patients With AML

How to Improve Adherence to Oral Medications in AML: Ask Patients

Reduced-Intensity Conditioning Regimen: Effect on Outcomes After Transplantation in AML

Thioridazine Under Study for Dopamine Receptor D2–Positive AML

What Is the Optimal Number of Chemotherapy Courses for Younger Patients With AML?

Large-Scale Study of AML, Venous Thromboembolism, and Hospitalization Rates

Maintenance Therapies After Hematopoietic Stem Cell Transplant in AML

Allogeneic HCT for AML: Long-Term Follow-up for Late Morbidities

First-in-Class LSD1 Inhibitor Under Study in Resistant AML

Combination of Venetoclax and Hypomethylating Agent for Favorable-Risk AML

Risk for Long-Term Complications in Younger Survivors of AML

Prognostic Power of Best Responses Under Study in Resistant AML

Integrated Palliative and Oncology Care for Patients With AML

Older Patients, Newly Diagnosed AML: Venetoclax-Based Combination Therapy

Treatment Advances in Secondary AML and Older Populations: The Age of Abundance

Allogeneic HSCT and AML: Prognostic Impact of Unsuccessful Cytogenetic Analysis at Baseline

Azacitidine Maintenance After Transplant in High-Risk AML

Pilot Program for Safely Administering Outpatient Chemotherapy Amid COVID-19

Novel PLK1 Inhibitor Plus Decitabine or Cytarabine Under Study in Resistant AML

TP53 Gene Mutations and Azacitidine Response in AML

Outpatient Chemotherapy Regimen Under Study in Pediatric AML

Marker Chromosome: Poor Prognostic Factor in AML After Allogeneic HSCT?

Beyond Survival: A Quality-Adjusted Analysis of Glasdegib in AML

Gene Mutations and Survival Outcomes in Older Patients With AML

Stem Cell Transplantation Followed by Cytarabine Chemotherapy for AML

Does Ibrutinib Enhance the Efficacy of Decitabine in AML?

Therapeutic Update in AML: Genomic Assessment Is Key

Lipid Core Nanoparticles Plus Etoposide With Transplantation for AML

Combination Therapy Under Study in Resistant FLT3-ITD–Mutated AML

Sorafenib Maintenance After Stem Cell Transplantation in FLT3-ITD AML

Update on Total-Body Irradiation in Children With de Novo AML

Therapeutic Considerations for Patients With AML Older Than Age 80

Can Dasatinib Overcome Resistance to FLT3 Inhibition in AML?

Can Immunoglobulin Expression Predict Survival in Patients With AML?

Link Between Cognitive Impairment and Outcomes in Older Recipients of Allogeneic HCT?

Low-Dose Cytarabine Plus Glasdegib in AML

Differentiation Syndrome With IDH Inhibitors in Resistant AML: FDA Analysis

Do CSF3R Mutations Affect Prognosis for Children With Favorable-Risk AML?

Secondary AML Risk Factors After Stem Cell Transplantation

Comparing AML Induction Regimens After Failure of Hypomethylating Agents

AML and Checkpoint Inhibitors: Outcomes With Cyclophosphamide After Transplantation

Venetoclax-Based Regimen for Patients With AML Ineligible for Intensive Chemotherapy

Predictors of Outcomes During Induction Chemotherapy for Patients With AML

Rare Case of Dual AML and Multiple Myeloma: Combination Therapy Active for Both

Busulfan Versus Melphalan: Long-Term Outcomes After Transplantation for AML

Long-Term Outcomes for Children With AML: Vietnamese Retrospective Study

Hematopoietic Stem Cell Transplantation for AML: Role of Genetic Mutation

Maintenance Selinexor After Allo-HCT for High-Risk AML

BRIGHT AML 1019 Trial to Study Glasdegib Plus Chemotherapy in Acute Myeloid Leukemia

Preserving Cardiac Function With Dexrazoxane in Pediatric Patients With AML

10-Year Data on Allo-HCT: Reduced-Intensity Versus Standard Conditioning Regimens

Fine-Tuning Cytarabine Treatment in Children With AML to Improve Outcomes

Feasibility of Outpatient Intensive Induction Chemotherapy for AML

Can Adding Venetoclax to FLAG-IDA Regimen Improve Outcomes in Patients With AML?

New Role Explored for Lenalidomide: With Chemotherapy for Older Patients With AML

Novel Combination of Lithium and Tretinoin for Treatment-Resistant AML

Additional Venetoclax-Inclusive Drug Combinations for Elderly Patients With AML

Aspacytarabine for Patients With AML Who Are Unfit for Standard Chemotherapy

Conditioning Intensity Before Transplantation May Affect Outcomes in AML

Sorafenib in FLT3/ITD-Positive AML: Impact of Co-occurring Mutations

Venetoclax-Based Regimen for Pediatric Patients With Resistant AML

Concordant AML in Twin Sisters: Impact of Prepubertal Cancer Treatment

Comparison of Conditioning Regimens Before Transplantation in Older Patients With AML

Can Early Cytogenetic Testing Improve Outcomes With HCT in AML?

Role of Isocitrate Dehydrogenase Inhibitors in AML Treatment

ADMIRAL Trial: Genetic Mutations in Patients With Resistant AML

Using Targeted Therapy in Older Patients With AML

Expression of Transcription Factors in Newly Diagnosed Acute Myeloid Leukemia

Epigenetic Alteration of HIST1 in Acute Myeloid Leukemia With NPM1 Mutation

Nivolumab Plus Front-Line Chemotherapy in Newly Diagnosed AML

How Does Gilteritinib Compare With Chemotherapy for FLT3 -Mutated AML?